Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

492029 NRG1-β1/HRG1-β1 EGF Domain, Human, Recombinant

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
View Products on Sigmaaldrich.com
492029
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Purity
≥97% by SDS-PAGE
Description
Overview

This product has been discontinued.



Recombinant, human neuregulin 1-β1/heregulin 1-β1 epidermal growth factor-like domain (NRG1-β1/HRG1-β1 EGF Domain), consisting of amino acids 176-246 and expressed in E. coli. All NRG1 isoforms contain an EGF-like domain that is required for binding directly to the ErbB3 or ErbB4 receptor tyrosine kinases.
Catalogue Number492029
Brand Family Calbiochem®
References
ReferencesBuonanno, A., and Fischbach, G.D. 2001. Curr. Opin. Neurobiol. 11, 287.
Adlkofer, K. and Lai, C. 2000. Glia 29, 104.
Garratt, A.N. et al. 2000. BioEssays 22, 987.
Karey, K.P., et al. 1988. Cancer Res. 48, 4083.
Product Information
FormLyophilized
FormulationLyophilized from 0.2 µm filtered acetonitrile, TFA, BSA.
Quality LevelMQ100
Applications
Biological Information
Biological activityED₅₀ = 0.06-0.3 ng/ml as measured in a serum-free proliferation assay using MCF-7 human breast adenocarcinoma cells.
Purity≥97% by SDS-PAGE
Physicochemical Information
ContaminantsEndotoxin: ≤1.0 EU/µg protein
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
492029 0

Documentation

NRG1-β1/HRG1-β1 EGF Domain, Human, Recombinant SDS

Title

Safety Data Sheet (SDS) 

NRG1-β1/HRG1-β1 EGF Domain, Human, Recombinant Certificates of Analysis

TitleLot Number
492029

References

Reference overview
Buonanno, A., and Fischbach, G.D. 2001. Curr. Opin. Neurobiol. 11, 287.
Adlkofer, K. and Lai, C. 2000. Glia 29, 104.
Garratt, A.N. et al. 2000. BioEssays 22, 987.
Karey, K.P., et al. 1988. Cancer Res. 48, 4083.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision22-June-2011 RFH
DescriptionRecombinant, human neuregulin 1-β1/heregulin 1-β1 epidermal growth factor-like domain (NRG1-β1/HRG1-β1 EGF Domain), consisting of amino acids 176-246 and expressed in E. coli. All NRG1 isoforms contain an EGF-like domain that is required for binding directly to the ErbB3 or ErbB4 receptor tyrosine kinases.
FormLyophilized
FormulationLyophilized from 0.2 µm filtered acetonitrile, TFA, BSA.
Purity≥97% by SDS-PAGE
ContaminantsEndotoxin: ≤1.0 EU/µg protein
Biological activityED₅₀ = 0.06-0.3 ng/ml as measured in a serum-free proliferation assay using MCF-7 human breast adenocarcinoma cells.
SolubilityReconstitute to 100 µg/ml with sterile PBS containing ≥1% human or bovine serum albumin.
Storage -20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesBuonanno, A., and Fischbach, G.D. 2001. Curr. Opin. Neurobiol. 11, 287.
Adlkofer, K. and Lai, C. 2000. Glia 29, 104.
Garratt, A.N. et al. 2000. BioEssays 22, 987.
Karey, K.P., et al. 1988. Cancer Res. 48, 4083.